FDA approves Regeneron’s Dupixent for bullous pemphigoid?
$1,919 Vol.
Rules
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Regeneron Pharmaceuticals’ biologics license application (BLA) or supplemental BLA (sBLA) for Dupixent® (dupilumab) as a treatment for bullous pemphigoid by June 20, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Created At: Jun 17, 2025, 7:12 PM UTC
Volume
$1,919End Date
Jun 20, 2025Created At
Jun 17, 2025, 7:12 PM UTCResolver
0x6A9D22261...Outcome proposed: Yes
No dispute
Final outcome: Yes
$1,919 Vol.
FDA approves Regeneron’s Dupixent for bullous pemphigoid?
About
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Regeneron Pharmaceuticals’ biologics license application (BLA) or supplemental BLA (sBLA) for Dupixent® (dupilumab) as a treatment for bullous pemphigoid by June 20, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No."
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application.
Conditional approvals may include post-marketing requirements or commitments and still qualify.
The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Volume
$1,919End Date
Jun 20, 2025Created At
Jun 17, 2025, 7:12 PM UTCResolver
0x6A9D22261...Outcome proposed: Yes
No dispute
Final outcome: Yes
Beware of external links.
Beware of external links.
Beware of external links.
Beware of external links.